Evommune, Inc. (EVMN)

Evommune Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Net Income	-68.87	-66.81	-34.05
Depreciation & Amortization	1.39	1.29	1
Loss (Gain) From Sale of Investments	-1.77	-1.82	-1.75
Stock-Based Compensation	5.86	1.72	1.48
Other Operating Activities	-8.93	-	-
Change in Accounts Payable	-0.84	6.51	0.13
Change in Unearned Revenue	-3	-	3
Change in Other Net Operating Assets	-0.28	0.92	0.22
Operating Cash Flow	-76.44	-58.2	-29.97
Capital Expenditures	-0.24	-0.09	-0.12
Investment in Securities	-115.07	-3.91	-48.32
Investing Cash Flow	-115.31	-3.99	-48.43
Long-Term Debt Repaid	-0.53	-0.42	-0.23
Net Debt Issued (Repaid)	-0.53	-0.42	-0.23
Issuance of Common Stock	157.29	0.01	0.01
Repurchase of Common Stock	-1.22	-	-
Financing Cash Flow	220.76	49.42	63.75
Net Cash Flow	29.02	-12.77	-14.65
Free Cash Flow	-76.68	-58.28	-30.09
Free Cash Flow Margin	-589.82%	-832.61%	-601.76%
Free Cash Flow Per Share	-12.49	-38.64	-24.01
Cash Interest Paid	0.01	0.03	0.06
Levered Free Cash Flow	-56.17	-20.45	-
Unlevered Free Cash Flow	-56.16	-20.43	-
Change in Working Capital	-4.12	7.42	3.34

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q